Cargando…
An open-label, phase I/II trial to determine the maximum tolerated dose and investigate safety, pharmacokinetics and efficacy of BI 836858, an unconjugated anti-CD33 monoclonal antibody, in combination with decitabine in patients with acute myeloid leukemia
| Autores principales: | , , , , , , , , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Fondazione Ferrata Storti
2022
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9713566/ https://www.ncbi.nlm.nih.gov/pubmed/36005556 http://dx.doi.org/10.3324/haematol.2022.281128 |
| _version_ | 1784842041863176192 |
|---|---|
| author | Fiedler, Walter Montesinos, Pau Schliemann, Christoph Middeke, Jan Vasu, Sumithira Scholz, Christian W. Esteve, Jordi Mondal, Shoubhik Rüter, Björn Burkard, Ute Osswald, Annika Blum, William |
| author_facet | Fiedler, Walter Montesinos, Pau Schliemann, Christoph Middeke, Jan Vasu, Sumithira Scholz, Christian W. Esteve, Jordi Mondal, Shoubhik Rüter, Björn Burkard, Ute Osswald, Annika Blum, William |
| author_sort | Fiedler, Walter |
| collection | PubMed |
| description | |
| format | Online Article Text |
| id | pubmed-9713566 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2022 |
| publisher | Fondazione Ferrata Storti |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-97135662022-12-12 An open-label, phase I/II trial to determine the maximum tolerated dose and investigate safety, pharmacokinetics and efficacy of BI 836858, an unconjugated anti-CD33 monoclonal antibody, in combination with decitabine in patients with acute myeloid leukemia Fiedler, Walter Montesinos, Pau Schliemann, Christoph Middeke, Jan Vasu, Sumithira Scholz, Christian W. Esteve, Jordi Mondal, Shoubhik Rüter, Björn Burkard, Ute Osswald, Annika Blum, William Haematologica Letter to the Editor Fondazione Ferrata Storti 2022-08-25 /pmc/articles/PMC9713566/ /pubmed/36005556 http://dx.doi.org/10.3324/haematol.2022.281128 Text en Copyright© 2022 Ferrata Storti Foundation https://creativecommons.org/licenses/by-nc/4.0/This article is distributed under the terms of the Creative Commons Attribution Noncommercial License (by-nc 4.0) which permits any noncommercial use, distribution, and reproduction in any medium, provided the original author(s) and source are credited. |
| spellingShingle | Letter to the Editor Fiedler, Walter Montesinos, Pau Schliemann, Christoph Middeke, Jan Vasu, Sumithira Scholz, Christian W. Esteve, Jordi Mondal, Shoubhik Rüter, Björn Burkard, Ute Osswald, Annika Blum, William An open-label, phase I/II trial to determine the maximum tolerated dose and investigate safety, pharmacokinetics and efficacy of BI 836858, an unconjugated anti-CD33 monoclonal antibody, in combination with decitabine in patients with acute myeloid leukemia |
| title | An open-label, phase I/II trial to determine the maximum tolerated dose and investigate safety, pharmacokinetics and efficacy of BI 836858, an unconjugated anti-CD33 monoclonal antibody, in combination with decitabine in patients with acute myeloid leukemia |
| title_full | An open-label, phase I/II trial to determine the maximum tolerated dose and investigate safety, pharmacokinetics and efficacy of BI 836858, an unconjugated anti-CD33 monoclonal antibody, in combination with decitabine in patients with acute myeloid leukemia |
| title_fullStr | An open-label, phase I/II trial to determine the maximum tolerated dose and investigate safety, pharmacokinetics and efficacy of BI 836858, an unconjugated anti-CD33 monoclonal antibody, in combination with decitabine in patients with acute myeloid leukemia |
| title_full_unstemmed | An open-label, phase I/II trial to determine the maximum tolerated dose and investigate safety, pharmacokinetics and efficacy of BI 836858, an unconjugated anti-CD33 monoclonal antibody, in combination with decitabine in patients with acute myeloid leukemia |
| title_short | An open-label, phase I/II trial to determine the maximum tolerated dose and investigate safety, pharmacokinetics and efficacy of BI 836858, an unconjugated anti-CD33 monoclonal antibody, in combination with decitabine in patients with acute myeloid leukemia |
| title_sort | open-label, phase i/ii trial to determine the maximum tolerated dose and investigate safety, pharmacokinetics and efficacy of bi 836858, an unconjugated anti-cd33 monoclonal antibody, in combination with decitabine in patients with acute myeloid leukemia |
| topic | Letter to the Editor |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9713566/ https://www.ncbi.nlm.nih.gov/pubmed/36005556 http://dx.doi.org/10.3324/haematol.2022.281128 |
| work_keys_str_mv | AT fiedlerwalter anopenlabelphaseiiitrialtodeterminethemaximumtolerateddoseandinvestigatesafetypharmacokineticsandefficacyofbi836858anunconjugatedanticd33monoclonalantibodyincombinationwithdecitabineinpatientswithacutemyeloidleukemia AT montesinospau anopenlabelphaseiiitrialtodeterminethemaximumtolerateddoseandinvestigatesafetypharmacokineticsandefficacyofbi836858anunconjugatedanticd33monoclonalantibodyincombinationwithdecitabineinpatientswithacutemyeloidleukemia AT schliemannchristoph anopenlabelphaseiiitrialtodeterminethemaximumtolerateddoseandinvestigatesafetypharmacokineticsandefficacyofbi836858anunconjugatedanticd33monoclonalantibodyincombinationwithdecitabineinpatientswithacutemyeloidleukemia AT middekejan anopenlabelphaseiiitrialtodeterminethemaximumtolerateddoseandinvestigatesafetypharmacokineticsandefficacyofbi836858anunconjugatedanticd33monoclonalantibodyincombinationwithdecitabineinpatientswithacutemyeloidleukemia AT vasusumithira anopenlabelphaseiiitrialtodeterminethemaximumtolerateddoseandinvestigatesafetypharmacokineticsandefficacyofbi836858anunconjugatedanticd33monoclonalantibodyincombinationwithdecitabineinpatientswithacutemyeloidleukemia AT scholzchristianw anopenlabelphaseiiitrialtodeterminethemaximumtolerateddoseandinvestigatesafetypharmacokineticsandefficacyofbi836858anunconjugatedanticd33monoclonalantibodyincombinationwithdecitabineinpatientswithacutemyeloidleukemia AT estevejordi anopenlabelphaseiiitrialtodeterminethemaximumtolerateddoseandinvestigatesafetypharmacokineticsandefficacyofbi836858anunconjugatedanticd33monoclonalantibodyincombinationwithdecitabineinpatientswithacutemyeloidleukemia AT mondalshoubhik anopenlabelphaseiiitrialtodeterminethemaximumtolerateddoseandinvestigatesafetypharmacokineticsandefficacyofbi836858anunconjugatedanticd33monoclonalantibodyincombinationwithdecitabineinpatientswithacutemyeloidleukemia AT ruterbjorn anopenlabelphaseiiitrialtodeterminethemaximumtolerateddoseandinvestigatesafetypharmacokineticsandefficacyofbi836858anunconjugatedanticd33monoclonalantibodyincombinationwithdecitabineinpatientswithacutemyeloidleukemia AT burkardute anopenlabelphaseiiitrialtodeterminethemaximumtolerateddoseandinvestigatesafetypharmacokineticsandefficacyofbi836858anunconjugatedanticd33monoclonalantibodyincombinationwithdecitabineinpatientswithacutemyeloidleukemia AT osswaldannika anopenlabelphaseiiitrialtodeterminethemaximumtolerateddoseandinvestigatesafetypharmacokineticsandefficacyofbi836858anunconjugatedanticd33monoclonalantibodyincombinationwithdecitabineinpatientswithacutemyeloidleukemia AT blumwilliam anopenlabelphaseiiitrialtodeterminethemaximumtolerateddoseandinvestigatesafetypharmacokineticsandefficacyofbi836858anunconjugatedanticd33monoclonalantibodyincombinationwithdecitabineinpatientswithacutemyeloidleukemia AT fiedlerwalter openlabelphaseiiitrialtodeterminethemaximumtolerateddoseandinvestigatesafetypharmacokineticsandefficacyofbi836858anunconjugatedanticd33monoclonalantibodyincombinationwithdecitabineinpatientswithacutemyeloidleukemia AT montesinospau openlabelphaseiiitrialtodeterminethemaximumtolerateddoseandinvestigatesafetypharmacokineticsandefficacyofbi836858anunconjugatedanticd33monoclonalantibodyincombinationwithdecitabineinpatientswithacutemyeloidleukemia AT schliemannchristoph openlabelphaseiiitrialtodeterminethemaximumtolerateddoseandinvestigatesafetypharmacokineticsandefficacyofbi836858anunconjugatedanticd33monoclonalantibodyincombinationwithdecitabineinpatientswithacutemyeloidleukemia AT middekejan openlabelphaseiiitrialtodeterminethemaximumtolerateddoseandinvestigatesafetypharmacokineticsandefficacyofbi836858anunconjugatedanticd33monoclonalantibodyincombinationwithdecitabineinpatientswithacutemyeloidleukemia AT vasusumithira openlabelphaseiiitrialtodeterminethemaximumtolerateddoseandinvestigatesafetypharmacokineticsandefficacyofbi836858anunconjugatedanticd33monoclonalantibodyincombinationwithdecitabineinpatientswithacutemyeloidleukemia AT scholzchristianw openlabelphaseiiitrialtodeterminethemaximumtolerateddoseandinvestigatesafetypharmacokineticsandefficacyofbi836858anunconjugatedanticd33monoclonalantibodyincombinationwithdecitabineinpatientswithacutemyeloidleukemia AT estevejordi openlabelphaseiiitrialtodeterminethemaximumtolerateddoseandinvestigatesafetypharmacokineticsandefficacyofbi836858anunconjugatedanticd33monoclonalantibodyincombinationwithdecitabineinpatientswithacutemyeloidleukemia AT mondalshoubhik openlabelphaseiiitrialtodeterminethemaximumtolerateddoseandinvestigatesafetypharmacokineticsandefficacyofbi836858anunconjugatedanticd33monoclonalantibodyincombinationwithdecitabineinpatientswithacutemyeloidleukemia AT ruterbjorn openlabelphaseiiitrialtodeterminethemaximumtolerateddoseandinvestigatesafetypharmacokineticsandefficacyofbi836858anunconjugatedanticd33monoclonalantibodyincombinationwithdecitabineinpatientswithacutemyeloidleukemia AT burkardute openlabelphaseiiitrialtodeterminethemaximumtolerateddoseandinvestigatesafetypharmacokineticsandefficacyofbi836858anunconjugatedanticd33monoclonalantibodyincombinationwithdecitabineinpatientswithacutemyeloidleukemia AT osswaldannika openlabelphaseiiitrialtodeterminethemaximumtolerateddoseandinvestigatesafetypharmacokineticsandefficacyofbi836858anunconjugatedanticd33monoclonalantibodyincombinationwithdecitabineinpatientswithacutemyeloidleukemia AT blumwilliam openlabelphaseiiitrialtodeterminethemaximumtolerateddoseandinvestigatesafetypharmacokineticsandefficacyofbi836858anunconjugatedanticd33monoclonalantibodyincombinationwithdecitabineinpatientswithacutemyeloidleukemia |